These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12702671)

  • 1. Experimental prediction of the natural evolution of antibiotic resistance.
    Barlow M; Hall BG
    Genetics; 2003 Apr; 163(4):1237-41. PubMed ID: 12702671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental prediction of the evolution of cefepime resistance from the CMY-2 AmpC beta-lactamase.
    Barlow M; Hall BG
    Genetics; 2003 May; 164(1):23-9. PubMed ID: 12750318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting evolutionary potential: in vitro evolution accurately reproduces natural evolution of the tem beta-lactamase.
    Barlow M; Hall BG
    Genetics; 2002 Mar; 160(3):823-32. PubMed ID: 11901104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting evolution by in vitro evolution requires determining evolutionary pathways.
    Hall BG
    Antimicrob Agents Chemother; 2002 Sep; 46(9):3035-8. PubMed ID: 12183265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural evolution of TEM-1 β-lactamase: experimental reconstruction and clinical relevance.
    Salverda ML; De Visser JA; Barlow M
    FEMS Microbiol Rev; 2010 Nov; 34(6):1015-36. PubMed ID: 20412308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of inoculum size on the antibacterial activity of cefpirome and cefepime against Klebsiella pneumoniae strains producing SHV extended-spectrum beta-lactamases.
    Bedenić B; Beader N; Zagar Z
    Clin Microbiol Infect; 2001 Nov; 7(11):626-35. PubMed ID: 11737087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs.
    Wang X; Minasov G; Shoichet BK
    J Mol Biol; 2002 Jun; 320(1):85-95. PubMed ID: 12079336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of TEM-, SHV- and CTX-M-type β-lactamase production among clinical isolates of Salmonella species.
    Elumalai S; Muthu G; Selvam REM; Ramesh S
    J Med Microbiol; 2014 Jul; 63(Pt 7):962-967. PubMed ID: 24866367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
    Susić E
    Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate.
    Barnaud G; Labia R; Raskine L; Sanson-Le Pors MJ; Philippon A; Arlet G
    FEMS Microbiol Lett; 2001 Feb; 195(2):185-90. PubMed ID: 11179650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substitution of Thr for Ala-237 in TEM-17, TEM-12 and TEM-26: alterations in beta-lactam resistance conferred on Escherichia coli.
    Giakkoupi P; Hujer AM; Miriagou V; Tzelepi E; Bonomo RA; Tzouvelekis LS
    FEMS Microbiol Lett; 2001 Jul; 201(1):37-40. PubMed ID: 11445164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cephalosporin substrate specificity determinants of TEM-1 beta-lactamase.
    Cantu C; Huang W; Palzkill T
    J Biol Chem; 1997 Nov; 272(46):29144-50. PubMed ID: 9360991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Beta-lactamases in laboratory and their role in resistance Part I.: Evolution of bacterial resistance mediated by beta-lactamases].
    Bedenić B
    Lijec Vjesn; 2004; 126(11-12):314-24. PubMed ID: 16082890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo selection of a complex mutant TEM (CMT) from an inhibitor-resistant TEM (IRT) during ceftazidime therapy.
    Jacquier H; Marcadé G; Raffoux E; Dombret H; Woerther PL; Donay JL; Arlet G; Cambau E
    J Antimicrob Chemother; 2013 Dec; 68(12):2792-6. PubMed ID: 23861309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cefepime (maxipime), large spectrum 4th generation cephalosporin, resistant to beta-lactamases].
    Angelescu M; Apostol A
    Chirurgia (Bucur); 2001; 96(6):547-52. PubMed ID: 12731231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis of why highly similar enzymes evolve differently.
    Majiduddin FK; Palzkill T
    Genetics; 2003 Feb; 163(2):457-66. PubMed ID: 12618385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase.
    Kang CI; Pai H; Kim SH; Kim HB; Kim EC; Oh MD; Choe KW
    J Antimicrob Chemother; 2004 Dec; 54(6):1130-3. PubMed ID: 15486080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic mutagenesis of the active site omega loop of TEM-1 beta-lactamase.
    Petrosino JF; Palzkill T
    J Bacteriol; 1996 Apr; 178(7):1821-8. PubMed ID: 8606154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-spectrum plasmid-mediated beta-lactamases.
    Sirot D
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():19-34. PubMed ID: 8543494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.
    Maglio D; Ong C; Banevicius MA; Geng Q; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2004 Jun; 48(6):1941-7. PubMed ID: 15155182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.